EUVIMEDEUVIMED entdecken
Open Access

How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice

Atefeh Hosseini, Elias Haj-Yehia, Sebastian Korste, Yalcin Kuzay, Marija Trajkovic-Arsic, Stephan Settelmeier, Miriam Cantore, Katja B Ferenz, Jens T Siveke, Ken Herrmann, Tienush Rassaf, Ulrike Hendgen-Cotta und 2 weitere

Journal of Nuclear Medicine · 2025-11 · 66 (11) · 1757-1763

DOI: 10.2967/jnumed.124.268860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 11.09.2025. Verfasst von Atefeh Hosseini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Membrane Proteins, Hypertension, Positron Emission Tomography Computed Tomography, Gelatinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reactive fibrosis is a complex response to chronic myocardial insults, contributing to heart failure progression. Fibroblast activation protein inhibitor (FAPI) PET shows promise in distinguishing active from established fibrosis. Although antifibrotic therapies may improve left ventricular (LV) function in preclinical studies, their clinical application is limited by the lack of noninvasive imaging methods to assess fibrosis regression. This study investigates the potential of FAPI PET to track the therapeutic transition of activated fibroblast activation protein (FAP)-positive fibroblasts toward a FAP-negative phenotype.

Methods

Mice were implanted with minipumps, infused with angiotensin-II/phenylephrine (Ang-II/PE) for 6 wk and scanned with 68Ga-FAPI-46 PET/CT longitudinally. Control mice received saline. 68Ga-FAPI-46 biodistribution studies were conducted at preselected time points, and FAPI uptake in the major organs was measured ex vivo. To assess the potential reversibility of the FAPI PET signal in the myocardium and liver, Ang-II/PE infusion was discontinued in a group of animals at 1 and 2 wk, respectively. LV structural and functional changes were assessed via echocardiography, tissue fibrosis via histology, and FAP expression via immunohistochemistry.

Results

Significant 68Ga-FAPI-46 uptake in the myocardium of treated mice peaked at 1 wk. An increase of 68Ga-FAPI-46 uptake was also observed in the liver, peaking at 2 wk, and decreased significantly at 4 wk. The PET signal declined to an indiscernible level in the heart and liver early after Ang-II/PE withdrawal. Three weeks after the removal of the minipumps, the hearts of mice previously exposed to Ang-II/PE for 1 wk exhibited a significant reduction in fibrosis compared with mice that were sacrificed immediately after 1 wk of Ang-II/PE infusion, without the 3-wk recovery period. Coinjection with excess unlabeled FAPI-46 reduced uptake in the heart, liver, and kidneys. Despite an increase in LV wall thickness at 1 wk, the ejection fraction remained stable initially but dropped significantly by 4 wk.

Conclusion

The rapid decline in PET signal after Ang-II/PE withdrawal shows that FAPI PET effectively visualizes dynamic changes in FAP expression, making it a valuable tool for quickly assessing treatment responses targeting activated fibroblasts. The cardiac FAPI signal precedes functional myocardial changes, indicating that FAPI PET could detect early fibrosis in cardiac remodeling leading to heart failure. FAPI PET may also visualize cardiac cirrhosis, a serious complication of cardiac disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsHypertensionPositron Emission Tomography Computed TomographyGelatinasesPositron-Emission TomographySerine EndopeptidasesHeart InjuriesAnimalsMiceFibrosisMaleEndopeptidasesMyocardiumMice, Inbred C57BLTime FactorsTissue DistributionGallium RadioisotopesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

FAPI PETrapid therapy response monitoringsignal reversibility

Substanzen

Membrane ProteinsEndopeptidasesGelatinasesSerine EndopeptidasesGallium RadioisotopesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • German Cancer Consortium, partner site Essen, a partnership between German Cancer Research Center and University Hospital Essen, Essen, Germany.
  • Institute of Physiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and.
  • Department of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany.

Zitieren

APA

Hosseini, A., Haj-Yehia, E., Korste, S., Kuzay, Y., Trajkovic-Arsic, M., Settelmeier, S., Cantore, M., Ferenz, K. B., Siveke, J. T., Herrmann, K., Rassaf, T., Hendgen-Cotta, U., Weber, W. A., & Varasteh, Z. (2025). How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice. Journal of Nuclear Medicine, 66(11), 1757-1763. https://doi.org/10.2967/jnumed.124.268860

Vancouver

Hosseini A, Haj-Yehia E, Korste S, Kuzay Y, Trajkovic-Arsic M, Settelmeier S, et al. How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice. Journal of Nuclear Medicine. 2025;66(11):1757-1763. doi:10.2967/jnumed.124.268860

BibTeX
@article{Hosseini2025,
  author = {Hosseini, Atefeh and Haj-Yehia, Elias and Korste, Sebastian and Kuzay, Yalcin and Trajkovic-Arsic, Marija and Settelmeier, Stephan and Cantore, Miriam and Ferenz, Katja B and Siveke, Jens T and Herrmann, Ken and Rassaf, Tienush and Hendgen-Cotta, Ulrike and Weber, Wolfgang A and Varasteh, Zohreh},
  title = {How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {11},
  pages = {1757--1763},
  doi = {10.2967/jnumed.124.268860}
}
Kostenlos starten →